Frequency of Conjunctivitis AES: Weeks 0–16

- Conjunctivitis was well tolerated and no cases were reported during the first 16 weeks of treatment.
- The frequency of conjunctivitis was similar in both the placebo and tralokinumab arms.

Additional Adverse Events of Relevance: Weeks 0–16

- There was one case of right eye pain reported on day 1, considered related to treatment.

Overall Summary of AES: Weeks 0–16

- Tralokinumab was well tolerated in pediatric patients aged 12–16 years with moderate-to-severe AD, with no new safety signals observed.
- No severe AEs or deaths were reported during the study.
- The frequency of moderate AEs was similar between the placebo and tralokinumab arms.

Conclusions

- Tralokinumab was well tolerated in pediatric patients aged 12–16 years with moderate-to-severe AD.
- The safety profile was consistent with the drug's approved indication.
- Tralokinumab demonstrated favorable safety characteristics in this adolescent patient group.

References